Paroxetine updated on 07-01-2025

Ear, face and neck anomalies

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7350
R21487		 Wemakor, 2015 Ear, face and neck 1st trimester case control unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 0.42 [0.03;6.83] C 0/27   746/17,802 746 27
ref
S5886
R14757		 Ban (Controls unexposed, disease free), 2014 Ear, face, and neck malformations 1st trimester retrospective cohort (claims database) unexposed, disease free Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.62 [0.10;26.19] C 0/1,200   83/325,294 83 1,200
ref
S6017
R15561		 Jimenez-Solem (Controls unexposed, NOS), 2012 Malformations of the ear, face and neck 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 8.32 [1.16;59.81] 1/568   -/843,797 - 568
ref
S7180
R20241		 Colvin, 2011 Congenital anomalies of ear, face, and neck 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 0.37 [0.02;5.90] C 0/572   224/94,561 224 572
ref
S7228
R20756		 Davis, 2007 Congenital anomalies of ear, face, and neck 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: no or not specified 1.30 [0.18;9.33] 1/182   210/49,654 211 182
ref
Total 5 studies 1.55 [0.49;4.91] 1,264 2,549
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Wemakor, 2015Wemakor, 2015 0.42[0.03; 6.83]7462715%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Ban (Controls unexposed, disease free), 2014Ban, 2014 1 1.62[0.10; 26.19]831,20015%ROB confusion: seriousROB selection: moderateROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Jimenez-Solem (Controls unexposed, NOS), 2012Jimenez-Solem, 2012 2 8.32[1.16; 59.81]-56827%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: critical Colvin, 2011Colvin, 2011 0.37[0.02; 5.90]22457215%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Davis, 2007Davis, 2007 1.30[0.18; 9.33]21118227%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (5 studies) I2 = 15% 1.55[0.49; 4.91]1,2642,5490.220.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, disease free; 2: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.95[0.55; 6.91]5182,52218%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 Colvin, 2011 Davis, 2007 4 case control studiescase control studies 0.42[0.03; 6.83]74627 -NAWemakor, 2015 1 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.55[0.49; 4.91]1,2642,54915%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 Colvin, 2011 Davis, 2007 5 Tags Adjustment   - No  - No 0.84[0.24; 2.92]1,2641,9810%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Colvin, 2011 Davis, 2007 4   - Yes  - Yes 8.32[1.16; 59.74]-568 -NAJimenez-Solem (Controls unexposed, NOS), 2012 1 Monotherapy   - no or not specified  - no or not specified 1.30[0.18; 9.36]211182 -NADavis, 2007 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 0.42[0.03; 6.83]74627 -NAWemakor, 2015 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.12[0.33; 13.48]3072,34040%NABan (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 Colvin, 2011 3 All studiesAll studies 1.55[0.49; 4.91]1,2642,54915%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 Colvin, 2011 Davis, 2007 50.120.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-3.43.81.7130.000Wemakor, 2015Ban (Controls unexposed, disease free), 2014Jimenez-Solem (Controls unexposed, NOS), 2012Colvin, 2011Davis, 2007

Asymetry test p-value = 0.1827 (by Egger's regression)

slope=5.2301 (2.7919); intercept=-4.0096 (2.3226); t=1.7263; p=0.1827

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.55[0.49; 4.91]1,2642,54915%NAWemakor, 2015 Ban (Controls unexposed, disease free), 2014 Jimenez-Solem (Controls unexposed, NOS), 2012 Colvin, 2011 Davis, 2007 50.510.01.0